Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 7/20 | 0.44 |
| ▸ | NPC1 | O15118 | 6/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 4/20 | 0.44 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 6/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.44 |
| ▸ | RELA | Q04206 | 2/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3310542 | 1.00 | MAOB (0.49) | MAOBCES2CES1MAOAPTPN1 | |
| SCHEMBL28381236 | 0.83 | NPC1 (0.47) | MAOBCES2CES1MAOAPTPN1 | |
| SCHEMBL15563662 | 0.83 | ALDH1A1 (0.49) | MAOBMAOAPTPN1MAPTNPC1 | |
| SCHEMBL15563661 | 0.83 | ALDH1A1 (0.49) | MAOBMAOAPTPN1MAPTNPC1 | |
| SCHEMBL1996269 | 0.82 | NPC1 (0.46) | MAOBCES2CES1MAOAPTPN1 | |
| SCHEMBL3308214 | 0.81 | PTPN1 (0.57) | MAOBCES2CES1MAOAPTPN1 | |
| SCHEMBL3308210 | 0.81 | PTPN1 (0.57) | MAOBCES2CES1MAOAPTPN1 | |
| SCHEMBL3308211 | 0.81 | PTPN1 (0.57) | MAOBCES2CES1MAOAPTPN1 | |
| SCHEMBL17064935 | 0.77 | MAPT (0.51) | MAOBCES2CES1PTPN1MAPT | |
| SCHEMBL12611223 | 0.77 | MAPT (0.51) | MAOBCES2CES1PTPN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171444-A1 | Inhibitors of Mycobacterium Tuberculosis Malate Synthase, Methods of Making and Uses Thereof | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2014-06-19 | — | — | US | claimed |
| US-20140171444-A1 | Inhibitors of Mycobacterium Tuberculosis Malate Synthase, Methods of Making and Uses Thereof | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2014-06-19 | — | — | US | disclosed |
| US-8664255-B2 | Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2014-03-04 | — | — | US | disclosed |
| US-20100113477-A1 | Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof | TEXAS A&M UNIVERSITY SYSTEM, THE | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113477-A1 | Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof | ME3, ME1, MDH1 | MAOB 638/4885CES2 1884/4885CES1 518/4885 |
| US-20140171444-A1 | Inhibitors of Mycobacterium Tuberculosis Malate Synthase, Methods of Making and Uses Thereof | ME3, ME1, MDH1 | MAOB 638/4885CES2 1884/4885CES1 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.